Loading...
XNASAMGN
Market cap141bUSD
Dec 20, Last price  
263.38USD
1D
0.84%
1Q
-21.93%
Jan 2017
80.14%
Name

Amgen Inc

Chart & Performance

D1W1MN
XNAS:AMGN chart
P/E
21.08
P/S
5.02
EPS
12.50
Div Yield, %
3.22%
Shrs. gr., 5y
-4.15%
Rev. gr., 5y
3.49%
Revenues
28.19b
+7.09%
10,550,000,00012,430,000,00014,268,000,00014,771,000,00015,003,000,00014,642,000,00015,053,000,00015,582,000,00017,265,000,00018,676,000,00020,063,000,00021,662,000,00022,991,000,00022,849,000,00023,747,000,00023,362,000,00025,424,000,00025,979,000,00026,323,000,00028,190,000,000
Net income
6.72b
+2.52%
2,363,000,0003,674,000,0002,950,000,0003,166,000,0004,196,000,0004,605,000,0004,627,000,0003,683,000,0004,345,000,0005,081,000,0005,158,000,0006,939,000,0007,722,000,0001,979,000,0008,394,000,0007,842,000,0007,264,000,0005,893,000,0006,552,000,0006,717,000,000
CFO
8.47b
-12.86%
3,697,000,0004,911,000,0005,389,000,0005,401,000,0005,988,000,0006,336,000,0005,787,000,0005,119,000,0005,882,000,0006,291,000,0008,555,000,0009,077,000,00010,354,000,00011,177,000,00011,296,000,0009,150,000,00010,497,000,0009,261,000,0009,721,000,0008,471,000,000
Dividend
Feb 14, 20250 USD/sh
Earnings
Feb 04, 2025

Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
URL
https://www.amgen.com/
IPO date
Jun 17, 1983
Employees
25,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
28,190,000
7.09%
26,323,000
1.32%
25,979,000
2.18%
Cost of revenue
19,365,000
16,254,000
16,641,000
Unusual Expense (Income)
NOPBT
8,825,000
10,069,000
9,338,000
NOPBT Margin
31.31%
38.25%
35.94%
Operating Taxes
1,138,000
794,000
808,000
Tax Rate
12.90%
7.89%
8.65%
NOPAT
7,687,000
9,275,000
8,530,000
Net income
6,717,000
2.52%
6,552,000
11.18%
5,893,000
-18.87%
Dividends
(4,556,000)
(4,196,000)
(4,013,000)
Dividend yield
2.94%
2.95%
3.11%
Proceeds from repurchase of equity
(6,360,000)
(4,975,000)
BB yield
4.48%
3.86%
Debt
Debt current
1,443,000
1,591,000
87,000
Long-term debt
64,552,000
37,893,000
33,747,000
Deferred revenue
(11,000)
Other long-term liabilities
6,315,000
8,419,000
9,059,000
Net debt
55,051,000
26,676,000
21,286,000
Cash flow
Cash from operating activities
8,471,000
9,721,000
9,261,000
CAPEX
(1,112,000)
(936,000)
(880,000)
Cash from investing activities
(26,204,000)
(6,044,000)
733,000
Cash from financing activities
21,048,000
(4,037,000)
(8,271,000)
FCF
2,419,000
9,032,000
8,235,000
Balance
Cash
10,944,000
9,305,000
8,037,000
Long term investments
3,503,000
4,511,000
Excess cash
9,534,500
11,491,850
11,249,050
Stockholders' equity
6,232,000
3,661,000
6,700,000
Invested Capital
71,619,000
46,158,000
41,667,000
ROIC
13.05%
21.12%
20.60%
ROCE
11.00%
20.21%
19.31%
EV
Common stock shares outstanding
538,000
541,000
573,000
Price
288.02
9.66%
262.64
16.74%
224.97
-2.15%
Market cap
154,954,760
9.06%
142,088,240
10.22%
128,907,810
-4.97%
EV
210,005,760
168,764,240
150,193,810
EBITDA
12,896,000
13,486,000
12,736,000
EV/EBITDA
16.28
12.51
11.79
Interest
2,875,000
1,406,000
1,197,000
Interest/NOPBT
32.58%
13.96%
12.82%